GH Research (GHRS) said Friday that it submitted a complete response to the US Food and Drug Administration for an investigational new drug application for GH001, its lead product candidate which is being developed as a medication for individuals with treatment-resistant depression.
The regulator previously placed the application on clinical hold, according to the company.
Shares of the biopharmaceutical company were up 2.1% in recent trading.
Price: 12.09, Change: +0.25, Percent Change: +2.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.